228 related articles for article (PubMed ID: 23576568)
1. Androgen-responsive serum response factor target genes regulate prostate cancer cell migration.
Verone AR; Duncan K; Godoy A; Yadav N; Bakin A; Koochekpour S; Jin JP; Heemers HV
Carcinogenesis; 2013 Aug; 34(8):1737-46. PubMed ID: 23576568
[TBL] [Abstract][Full Text] [Related]
2. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy.
Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV
Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064
[TBL] [Abstract][Full Text] [Related]
3. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.
Heemers HV
Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924
[TBL] [Abstract][Full Text] [Related]
4. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
5. Relationship between serum response factor and androgen receptor in prostate cancer.
Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
7. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance.
Zennami K; Choi SM; Liao R; Li Y; Dinalankara W; Marchionni L; Rafiqi FH; Kurozumi A; Hatano K; Lupold SE
Mol Cancer Res; 2019 Feb; 17(2):618-627. PubMed ID: 30518628
[TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages.
Lee GT; Jung YS; Ha YS; Kim JH; Kim WJ; Kim IY
Cancer Sci; 2013 Aug; 104(8):1027-32. PubMed ID: 23710822
[TBL] [Abstract][Full Text] [Related]
9. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
11. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance.
Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF
Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444
[TBL] [Abstract][Full Text] [Related]
12. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.
Colditz J; Rupf B; Maiwald C; Baniahmad A
Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825
[TBL] [Abstract][Full Text] [Related]
13. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
[TBL] [Abstract][Full Text] [Related]
14. Androgen-induced cell migration: role of androgen receptor/filamin A association.
Castoria G; D'Amato L; Ciociola A; Giovannelli P; Giraldi T; Sepe L; Paolella G; Barone MV; Migliaccio A; Auricchio F
PLoS One; 2011 Feb; 6(2):e17218. PubMed ID: 21359179
[TBL] [Abstract][Full Text] [Related]
15. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
Fiandalo MV; Wu W; Mohler JL
Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
[TBL] [Abstract][Full Text] [Related]
16. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
17. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
19. Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
Wang T; Song W; Chen Y; Chen R; Liu Z; Wu L; Li M; Yang J; Wang L; Liu J; Ye Z; Wang C; Chen K
Clin Cancer Res; 2016 Mar; 22(6):1531-44. PubMed ID: 26527749
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]